Enhabit (EHAB) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2023	Nov. 08, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-41406
Entity Registrant Name	Enhabit, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-2409192
Entity Address, Address Line One	6688 N. Central Expressway
Entity Address, Address Line Two	Suite 1300
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75206
City Area Code	214
Local Phone Number	239-6500
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	EHAB
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		50,129,596
Entity Central Index Key	0001803737
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net service revenue	$ 258,300,000	$ 265,700,000	$ 785,700,000	$ 808,000,000
Revenue, Product and Service [Extensible Enumeration]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
Cost of service, excluding depreciation and amortization	$ 134,000,000	$ 132,300,000	$ 402,100,000	$ 392,300,000
Cost, Product and Service [Extensible Enumeration]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
General and administrative expenses	$ 108,800,000	$ 107,500,000	$ 327,100,000	$ 310,400,000
Depreciation and amortization	7,700,000	8,000,000	23,200,000	24,700,000
Impairment of goodwill	0	0	85,800,000	0
Operating income (loss)	7,800,000	17,900,000	(52,500,000)	80,600,000
Interest expense and amortization of debt discounts and fees	10,900,000	6,200,000	30,700,000	6,300,000
Other income	(100,000)	0	(200,000)	0
(Loss) income before income taxes and noncontrolling interests	(3,000,000)	11,700,000	(83,000,000)	74,300,000
Income tax (benefit) expense	(800,000)	2,800,000	(9,900,000)	17,900,000
Net (loss) income	(2,200,000)	8,900,000	(73,100,000)	56,400,000
Less: Net income attributable to noncontrolling interests	200,000	300,000	1,000,000	1,600,000
Net (loss) income attributable to Enhabit, Inc.	$ (2,400,000)	$ 8,600,000	$ (74,100,000)	$ 54,800,000
Weighted average common shares outstanding:
Basic (in shares)	49.9	49.6	49.8	49.6
Diluted (in shares)	49.9	49.7	49.8	49.7
(Loss) earnings per common share:
Basic (loss) earnings per share attributable to Enhabit, Inc. common stockholders (in dollars per share)	$ (0.05)	$ 0.17	$ (1.48)	$ 1.10
Diluted (loss) earnings per share attributable to Enhabit, Inc. common stockholders (in dollars per share)	$ (0.05)	$ 0.17	$ (1.48)	$ 1.10

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net (loss) income including noncontrolling interest	$ (2.2)	$ 8.9	$ (73.1)	$ 56.4
Other comprehensive income:
Unrealized gain on cash flow hedges, net of tax of $0.2, $—, $0.8, and $—, respectively	0.7	0	2.3	0
Total other comprehensive income	0.7	0	2.3	0
Comprehensive (loss) income including noncontrolling interest	(1.5)	8.9	(70.8)	56.4
Less: Comprehensive income attributable to noncontrolling interest	0.2	0.3	1	1.6
Comprehensive (loss) income attributable to Enhabit, Inc.	$ (1.7)	$ 8.6	$ (71.8)	$ 54.8

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Income (Parentheticals) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Unrealized gain on cash flow hedges, tax	$ 0.2	$ 0	$ 0.8	$ 0

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions		Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents		$ 31.6	$ 22.9
Restricted cash		3.6	4.3
Accounts receivable		167.8	149.6
Income tax receivable		2.7	11.4
Prepaid expenses and other current assets		12.1	23.6
Total current assets		217.8	211.8
Property and equipment, net		20.1	20.4
Operating lease right-of-use assets		60	42
Goodwill		1,061.7	1,144.8
Intangible assets, net		85.9	102.6
Other long-term assets		5.4	5.2
Total assets	[1]	1,450.9	1,526.8
Current liabilities:
Current portion of long-term debt		22.6	23.1
Current operating lease liabilities		12.7	14
Accounts payable		6	3.8
Accrued payroll		48.6	35.5
Refunds due patients and other third-party payors		7.8	8.3
Accrued medical insurance		8.4	7.5
Other current liabilities		36.9	40.7
Total current liabilities		143	132.9
Long-term debt, net of current portion		535.8	560
Long-term operating lease liabilities		47	28.1
Deferred income tax liabilities		16.3	28.6
Other long-term liabilities		0	1.9
Total liabilities		742.1	751.5
Commitments and contingencies
Redeemable noncontrolling interests		5	5.2
Enhabit, Inc. stockholders’ equity:
Common stock, $.01 par value; 200,000,000 shares authorized; issued: 50,174,888 as of September 30, 2023 and 50,099,716 as of December 31, 2022		0.5	0.5
Capital in excess of par value		414.1	406.9
Accumulated other comprehensive income		1.6	(0.7)
Retained earnings		260.9	335
Treasury stock at cost, 74,947 and — shares, respectively		(0.5)	0
Total Enhabit, Inc. stockholders’ equity		676.6	741.7
Noncontrolling interests		27.2	28.4
Total stockholders’ equity		703.8	770.1
Total liabilities and stockholders' equity	[1]	$ 1,450.9	$ 1,526.8
[1] Our consolidated assets as of September 30, 2023 and December 31, 2022 include total assets of variable interest entities of $18.7 million and $20.6 million, respectively, that cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September 30, 2023 and December 31, 2022 include total liabilities of the variable interest entities of $1.3 million and $0.5 million, respectively. See Note 2, Variable Interest Entities .

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions		Sep. 30, 2023	Dec. 31, 2022
Common stock, par value (in dollars per share)		$ 0.01	$ 0.01
Common stock, shares authorized (in shares)		200,000,000	200,000,000
Common stock, shares issued (in shares)		50,174,888	50,099,716
Treasury stock (in shares)		74,947	0
Assets	[1]	$ 1,450.9	$ 1,526.8
Liabilities		742.1	751.5
VIE, Primary Beneficiary
Assets		18.7	20.6
Liabilities		$ 1.3	$ 0.5
[1] Our consolidated assets as of September 30, 2023 and December 31, 2022 include total assets of variable interest entities of $18.7 million and $20.6 million, respectively, that cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September 30, 2023 and December 31, 2022 include total liabilities of the variable interest entities of $1.3 million and $0.5 million, respectively. See Note 2, Variable Interest Entities .

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Millions	Total	Common Stock	Capital in Excess of Par Value	Other Comprehensive Income	Retained Earnings	Treasury Stock	Noncontrolling Interests
Number of common shares outstanding, beginning balance (in shares) at Dec. 31, 2021		49,600,000
Number of treasury shares outstanding, beginning balance (in shares) at Dec. 31, 2021						0
Balance at beginning of period at Dec. 31, 2021	$ 1,478.3	$ 0.5	$ 1,094.1	$ 0	$ 375.4	$ 0	$ 8.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	56.4				54.8		1.6
Other comprehensive income, net of tax	0
Capital contributions	62.3		62.3
Capital distributions	(759.1)		(759.1)
Distributions declared	(0.9)						(0.9)
Stock-based compensation expense	4.5		4.5
Saint Alphonsus acquisition	15.9						15.9
Contributions from noncontrolling interests of consolidated affiliates	6.4		2.9				3.5
Number of common shares outstanding, ending balance (in shares) at Sep. 30, 2022		49,600,000
Number of treasury shares outstanding, ending balance (in shares) at Sep. 30, 2022						0
Balance at end of period at Sep. 30, 2022	863.8	$ 0.5	404.7	0	430.2	$ 0	28.4
Number of common shares outstanding, beginning balance (in shares) at Jun. 30, 2022		49,600,000
Number of treasury shares outstanding, beginning balance (in shares) at Jun. 30, 2022						0
Balance at beginning of period at Jun. 30, 2022	850.7	$ 0.5	400.2	0	421.6	$ 0	28.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	8.9				8.6		0.3
Other comprehensive income, net of tax	0
Distributions declared	(0.3)						(0.3)
Stock-based compensation expense	4.5		4.5
Number of common shares outstanding, ending balance (in shares) at Sep. 30, 2022		49,600,000
Number of treasury shares outstanding, ending balance (in shares) at Sep. 30, 2022						0
Balance at end of period at Sep. 30, 2022	$ 863.8	$ 0.5	404.7	0	430.2	$ 0	28.4
Number of common shares outstanding, beginning balance (in shares) at Dec. 31, 2022		50,100,000
Number of treasury shares outstanding, beginning balance (in shares) at Dec. 31, 2022	0					0
Balance at beginning of period at Dec. 31, 2022	$ 770.1	$ 0.5	406.9	(0.7)	335	$ 0	28.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(73.1)				(74.1)		1
Other comprehensive income, net of tax	2.3			2.3
Distributions declared	(2.2)						(2.2)
Stock-based compensation expense	7.2		7.2
Restricted stock forfeited, including forfeitures due to net share settlement of income taxes(in shares)						100,000
Restricted stock forfeited, including forfeitures due to net share settlement of income taxes	$ (0.5)					$ (0.5)
Number of common shares outstanding, ending balance (in shares) at Sep. 30, 2023		50,100,000
Number of treasury shares outstanding, ending balance (in shares) at Sep. 30, 2023	74,947					100,000
Balance at end of period at Sep. 30, 2023	$ 703.8	$ 0.5	414.1	1.6	260.9	$ (0.5)	27.2
Number of common shares outstanding, beginning balance (in shares) at Jun. 30, 2023		50,100,000
Number of treasury shares outstanding, beginning balance (in shares) at Jun. 30, 2023						100,000
Balance at beginning of period at Jun. 30, 2023	702.1	$ 0.5	411	0.9	263.3	$ (0.5)	26.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(2.1)				(2.4)		0.3
Other comprehensive income, net of tax	0.7			0.7
Stock-based compensation expense	$ 3.1		3.1
Number of common shares outstanding, ending balance (in shares) at Sep. 30, 2023		50,100,000
Number of treasury shares outstanding, ending balance (in shares) at Sep. 30, 2023	74,947					100,000
Balance at end of period at Sep. 30, 2023	$ 703.8	$ 0.5	$ 414.1	$ 1.6	$ 260.9	$ (0.5)	$ 27.2

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net (loss) income	$ (73,100,000)	$ 56,400,000
Adjustments to reconcile net (loss) income to net cash provided by operating activities—
Depreciation and amortization	23,200,000	24,700,000
Amortization of debt related costs	1,000,000	300,000
Impairment of goodwill	85,800,000	0
Stock-based compensation	7,200,000	7,100,000
Deferred tax benefit	(13,100,000)	(2,500,000)
Other, net	700,000	0
Changes in assets and liabilities, net of acquisitions—
Accounts receivable	(17,800,000)	16,400,000
Prepaid expenses and other assets	19,900,000	(22,500,000)
Accounts payable	2,200,000	(200,000)
Accrued payroll	13,100,000	(3,300,000)
Other liabilities	(3,600,000)	(400,000)
Net cash provided by operating activities	45,500,000	76,000,000
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired	(2,800,000)	0
Purchases of property and equipment	(3,100,000)	(5,300,000)
Additions to capitalized software costs	(500,000)	0
Other, net	600,000	1,200,000
Net cash used in investing activities	(5,800,000)	(4,100,000)
Cash flows from financing activities:
Principal borrowings on term loan	0	400,000,000
Principal payments on term loan	(15,000,000)	(5,000,000)
Principal payments on debt	0	(400,000)
Borrowings on revolving credit facility	0	170,000,000
Payments on revolving credit facility	(10,000,000)	0
Principal payments under finance lease obligations	(2,600,000)	(3,600,000)
Debt issuance costs	(1,100,000)	0
Distributions paid to noncontrolling interests of consolidated affiliates	(2,500,000)	0
Contributions from Encompass	0	59,800,000
Distributions to Encompass	0	(654,900,000)
Contributions from noncontrolling interests of consolidated affiliates	0	7,400,000
Other	(500,000)	(5,300,000)
Net cash used in financing activities	(31,700,000)	(32,000,000)
Increase in cash, cash equivalents, and restricted cash	8,000,000	39,900,000
Cash, cash equivalents, and restricted cash at beginning of year	27,200,000	8,000,000
Cash, cash equivalents, and restricted cash at end of period	35,200,000	47,900,000
Supplemental cash flow information:
Cash (received) paid for income taxes, net	(5,400,000)
Cash (received) paid for income taxes, net		11,800,000
Cash paid for interest	27,900,000	6,000,000
Supplemental schedule of noncash activities:
Property and equipment additions through finance leases	2,700,000	2,900,000
Operating lease additions	29,300,000	5,900,000
Trade name transfer to Encompass (including deferred tax liability)	$ 0	$ (104,200,000)

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies: Organization and Description of Business — Enhabit, Inc. (“Enhabit,” “we,” “us,” “our,” and the “Company”), incorporated in Delaware in 2014, provides a comprehensive range of Medicare-certified skilled home health and hospice services in 34 states, with a concentration in the southern half of the United States. We manage our operations and disclose financial information using two reportable segments: (1) home health and (2) hospice. See Note 9, Segment Reporting . Prior to July 1, 2022, the Company operated as a reporting segment of Encompass Health Corporation (“Encompass”). Separation from Encompass — On December 9, 2020, Encompass announced a formal process to explore strategic alternatives for its home health and hospice business. On January 19, 2022, Encompass announced its home health and hospice business would be rebranded and operate under the name Enhabit Home Health & Hospice. In March 2022, we changed our name from Encompass Health Home Health Holdings, Inc. to Enhabit, Inc. On July 1, 2022, Encompass completed the separation of the Company through the distribution of all of the outstanding shares of common stock, par value $0.01 per share, of Enhabit to the stockholders of record of Encompass (the “Distribution”) as of the close of business on June 24, 2022 (the “Record Date”). The Distribution was effective at 12:01 a.m., Eastern Time, on July 1, 2022. The Distribution was structured as a pro rata distribution of one share of Enhabit common stock for every two shares of Encompass common stock held of record as of the Record Date. No fractional shares were distributed. A cash payment was made in lieu of any fractional shares. As a result of the Distribution, Enhabit is now an independent public company and its common stock is listed under the symbol “EHAB” on the New York Stock Exchange (the “Separation”). The Separation was completed pursuant to a separation and distribution agreement (the “Separation and Distribution Agreement”) and other agreements with Encompass related to the Separation, including, but not limited to, a tax matters agreement (the “Tax Matters Agreement”), an employee matters agreement (the “Employee Matters Agreement”), and a transition services agreement (the “Transition Services Agreement” or “TSA”). Following the Separation, certain functions continue to be provided by Encompass under the TSA or are being performed using the Company’s own resources or third‑party providers. The Company incurred certain costs in its establishment as an independent, publicly traded company and expects to incur ongoing additional costs associated with operating as an independent, publicly traded company. In anticipation of the Distribution, we transferred the “Encompass” trade name with a book value of $135.2 million and the related deferred tax liabilities with a book value of $31.0 million to Encompass as they will continue to operate under the Encompass brand. See also Note 4, Long-term Debt. Strategic Alternatives Process — On August 23, 2023, we announced a formal process to explore strategic alternatives for our business. Our Board is considering a range of options, including, among other things, a potential sale, merger or other strategic transaction. Certain transactions involving the Company remain subject to additional conditions in the Tax Matters Agreement, including securing a tax opinion that such proposed transaction would not jeopardize the tax-free treatment of the Separation, satisfactory to Encompass in its sole and absolute discretion. No timetable has been established for the completion of the strategic review. Basis of Presentation and Consolidation — The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries should be read in conjunction with the audited consolidated financial statements and accompanying notes contained in the Company’s Annual Report for the year ended December 31, 2022 on Form 10-K (the “Form 10-K”) filed with the United States Securities and Exchange Commission (the “SEC”) on April 14, 2023. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December 31, 2022 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading. The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying unaudited condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented. Prior to July 1, 2022, we existed and functioned as part of the consolidated business of Encompass. The results related to the periods prior to July 1, 2022 included within the accompanying unaudited condensed consolidated financial statements have been derived from the unaudited condensed consolidated financial statements and accounting records of Encompass as if the Company had operated on a stand-alone basis during the periods presented and were prepared utilizing the legal entity approach, in accordance with GAAP, and pursuant to the rules and regulations of the SEC. Prior to July 1, 2022, the Company was reported as a single reportable segment within Encompass’s reportable segments and did not operate as a stand-alone company. Accordingly, Encompass historically reported the financial position and the related results of operations, cash flows, and changes in equity of the Company as a component of Encompass’s unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements include an allocation of expenses related to certain Encompass corporate functions as discussed in Note 10, Related Party Transactions, for periods prior to July 1, 2022. The unaudited condensed consolidated financial statements also include revenues and expenses directly attributable to the Company and assets and liabilities specifically attributable to the Company. Encompass’s third-party debt and related interest expense have not been attributed to the Company because the Company was not the primary legal obligor of the debt and the borrowings were not specifically identifiable to the Company. However, subsequent to April 23, 2020, the Company was a guarantor for Encompass’s credit agreement and senior debt. In connection with the Distribution, the Company was released from its guarantee of Encompass’s indebtedness. The Company maintains its own cash management system and did not participate in a centralized cash management arrangement with Encompass. The income tax amounts in these unaudited condensed consolidated financial statements for the periods prior to July 1, 2022 have been calculated based on a separate return methodology and are presented as if our income gave rise to separate federal and state consolidated income tax return filing obligations in the respective jurisdictions in which we operate. In addition to various separate state and local income tax filings, we joined with Encompass in various U.S. federal, state and local consolidated income tax filings prior to the Separation. See Note 6, Income Taxes , for information related to our Tax Sharing Agreement with Encompass. The unaudited condensed consolidated financial statements include the assets, liabilities, revenues, and expenses of all wholly owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest. We use the equity method to account for our investments in entities we do not control, but for which we have the ability to exercise significant influence over operating and financial policies. Consolidated Net (loss) income attributable to Enhabit, Inc. includes our share of the net earnings of these entities. We eliminate all intercompany accounts and transactions within the Company from our financial results. Transactions between the Company and Encompass have been included in these unaudited condensed consolidated financial statements. The transfers with Encompass that were not settled in cash are reflected in stockholders’ equity on the condensed consolidated balance sheets and within Capital in Excess of Par Value on the condensed consolidated statements of stockholders’ equity. Within the condensed consolidated statements of cash flows, these transfers were treated as an operating, financing or noncash activity determined by the nature of the transaction. For the periods prior to July 1, 2022, transactions between the Company and Encompass were considered related party transactions. Refer to Note 10, Related Party Transactions , for more information. Net Service Revenue— Our Net service revenue disaggregated by payor source and segment are as follows (in millions): Home Health Hospice Consolidated Three Months Ended Three Months Ended Three Months Ended 2023 2022 2023 2022 2023 2022 Medicare $ 141.0 $ 159.1 $ 46.7 $ 47.3 $ 187.7 $ 206.4 Medicare Advantage 45.7 38.5 — — 45.7 38.5 Managed care 21.2 15.2 — 1.7 21.2 16.9 Medicaid 2.9 3.3 0.7 0.4 3.6 3.7 Other 0.1 0.2 — — 0.1 0.2 Total $ 210.9 $ 216.3 $ 47.4 $ 49.4 $ 258.3 $ 265.7 Home Health Hospice Consolidated Nine Months Ended Nine Months Ended Nine Months Ended 2023 2022 2023 2022 2023 2022 Medicare $ 426.5 $ 492.5 $ 140.5 $ 141.4 $ 567.0 $ 633.9 Medicare Advantage 148.3 110.3 — — 148.3 110.3 Managed care 56.5 49.2 4.3 4.3 60.8 53.5 Medicaid 8.7 8.9 0.4 0.9 9.1 9.8 Other 0.5 0.5 — — 0.5 0.5 Total $ 640.5 $ 661.4 $ 145.2 $ 146.6 $ 785.7 $ 808.0 For a discussion of our significant accounting policies, including our policy related to Net service revenue, see Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements included in the Form 10-K. Redeemable Noncontrolling Interests in Consolidated Affiliates — Certain of our joint venture agreements contain provisions that allow our partners to require us to purchase their interests in the joint venture at fair value at certain points in the future. These put rights include termination provisions, change in control provisions, and breaches of the terms of the underlying operating agreements. Because these noncontrolling interests provide for redemption features that are not solely within our control, we classify them as Redeemable noncontrolling interests outside of permanent equity in our consolidated balance sheets. The following tables reconcile the net income attributable to nonredeemable Noncontrolling interests , as recorded in the shareholders’ equity section of the consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests , as recorded in the mezzanine section of the consolidated balance sheets, to the Net income attributable to noncontrolling interests presented in the consolidated statements of income (in millions): Nine Months Ended September 30, 2023 2022 Balance at beginning of period $ 5.2 $ 5.0 Purchases of redeemable noncontrolling interests — 0.2 Distributions to redeemable noncontrolling interests (0.2) — Balance at end of period $ 5.0 $ 5.2 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net income attributable to nonredeemable noncontrolling interests $ 0.3 $ 0.3 $ 1.0 $ 1.6 Net income attributable to redeemable noncontrolling interests (0.1) — — — Net income attributable to noncontrolling interests $ 0.2 $ 0.3 $ 1.0 $ 1.6 (Loss) Earnings Per Common Share — The following table sets forth the computation of diluted weighted average common shares outstanding for the three and nine months ended September 30, 2023 and 2022 (in millions): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Weighted average common shares outstanding: Basic 49.9 49.6 49.8 49.6 Dilutive effect of restricted stock, restricted stock units and performance units — 0.1 — 0.1 Diluted 49.9 49.7 49.8 49.7 A total of 0.3 million options to purchase Enhabit’s shares and 1.5 million shares of restricted stock awards, performance units, and restricted stock units were excluded from the diluted weighted average common shares outstanding for the three and nine months ended September 30, 2023 because their effects were antidilutive. A total of 0.2 million options to purchase Enhabit’s shares and 0.7 million shares of restricted stock awards, performance units, and restricted stock units were excluded from the diluted weighted average common shares outstanding for the three and nine months ended September 30, 2022 because their effects were anti-dilutive. See Note 10, Stock-Based Payments , to the consolidated financial statements included in the Form 10-K for additional information. Recent Accounting Pronouncements — We do not believe any recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.

Variable Interest Entities (VIE

Variable Interest Entities (VIEs)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities (VIEs)	Variable Interest Entities (“VIEs”):As of September 30, 2023 and December 31, 2022, we consolidated two limited partnership-like entities that are VIEs and of which we are the primary beneficiary. Our ownership percentages in these entities are 60% and 90% as of September 30, 2023. Through partnership and management agreements with or governing these entities, we manage these entities and handle all day-to-day operating decisions. Accordingly, we have the decision-making power over the activities that most significantly impact the economic performance of the VIEs and an obligation to absorb losses or receive benefits from the VIEs that could potentially be significant to the VIEs. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections, and creation and maintenance of medical records. The terms of the agreements governing the VIEs prohibit us from using the assets of the VIEs to satisfy the obligations of other entities. The carrying amounts and classifications of the consolidated VIEs’ assets and liabilities, which are included in our condensed consolidated balance sheets, are as follows (in millions): September 30, December 31, Assets Current assets: Restricted cash $ 3.0 $ 4.0 Accounts receivable 2.3 2.9 Total current assets 5.3 6.9 Operating lease right-of-use assets 0.1 0.2 Goodwill 12.4 12.4 Intangible assets, net 0.9 1.1 Total assets $ 18.7 $ 20.6 Liabilities Current liabilities: Current operating lease liabilities $ 0.1 $ 0.1 Accrued payroll 0.3 0.2 Other current liabilities 0.8 0.1 Total current liabilities 1.2 0.4 Long-term operating lease liabilities 0.1 — Other long-term liabilities — 0.1 Total liabilities $ 1.3 $ 0.5

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets: We are required to test our goodwill for impairment at least annually, as of October 1, or more frequently if events or changes in circumstances indicate that it is more likely than not goodwill is impaired. During the preparation of our consolidated financial statements for the year ended December 31, 2022, we identified potential impairment triggering events in the fourth quarter and determined a quantitative analysis of our two reporting units should be performed. These triggering events included lower than expected fourth quarter operating results, a change in our acquisition strategy, and declining collections, which we believe is in part a result of the growing shift in our third‑party payor mix, and specifically, an increase in Medicare Advantage payors. During the three months ended June 30, 2023, we identified potential impairment triggering events in the quarter and determined a quantitative analysis of our two reporting units should be performed. These triggering events included our performance against the 2023 forecast, a decrease in our share price and market capitalization, and the release of the 2024 proposed rule for home health on June 30, 2023, which included a net negative home health payment update. During the three months ended September 30, 2023, we identified potential impairment triggering events in the quarter and determined a quantitative analysis of our two reporting units should be performed. These triggering events included our performance against the 2023 forecast and a decrease in our share price and market capitalization. We estimated the fair value of our reporting units using both the income approach and market approach. The assumptions used in the income approach incorporate a number of significant estimates and judgments, including revenue growth rates, timing of acquisitions and de novo openings, forecasted operating margins, and the weighted-average cost of capital. The market approach utilizes the guideline public company methodology, which uses valuation indicators, including market multiples of earnings before interest, taxes, depreciation, and amortization, from other businesses that are similar to each reporting unit and implied control premiums. While management believes the assumptions used are reasonable and commensurate with the views of a market participant, there is also uncertainty in current general economic and market conditions. The result of the analysis is sensitive to changes in key assumptions, such as assumed future reimbursement rates, rising interest rates and labor costs, and delays in our ability to complete acquisitions and de novo openings, which could negatively impact our forecasted cash flows and result in an impairment charge in future periods. Based on the quantitative analysis in the fourth quarter of 2022, we recorded an impairment charge of $109.0 million in the three months ended December 31, 2022 to reflect a decrease in the carrying value of our home health reporting unit. As of December 31, 2022, the fair value of our hospice reporting unit exceeded its carrying value by less than 15%. As of December 31, 2022, the hospice reporting unit had an allocated goodwill balance of $303.6 million. Based on the quantitative analysis in the second quarter of 2023, we recorded an impairment charge of $85.8 million for the three months ended June 30, 2023 to reflect a decrease in the carrying value of our hospice reporting unit. As of June 30, 2023, the hospice reporting unit had an allocated goodwill balance of $217.8 million. As of June 30, 2023, the home health reporting unit had an allocated goodwill balance of $843.9 million. No impairment was identified as a result of the quantitative analysis in the third quarter of 2023. The cumulative impairments to our goodwill totaled $109.0 million as of December 31, 2022 and $194.8 million as of September 30, 2023. Based on the quantitative analysis, the fair value of our home health reporting unit as of September 30, 2023 exceeded its carrying value by less than 7%. As of September 30, 2023, the home health reporting unit had an allocated goodwill balance of $843.9 million. The fair value of the hospice reporting unit as of September 30, 2023 exceeded its carrying value by less than 5%. As of September 30, 2023, the hospice reporting unit had an allocated goodwill balance of $217.8 million.

Long-term Debt

Long-term Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Long-term Debt	Long-term Debt: Our long-term debt outstanding consists of the following (in millions): September 30, December 31, 2022 Credit Agreement— Advances under revolving credit facility $ 180.0 $ 190.0 Term loan A facility 373.1 387.9 Finance lease obligations 5.3 5.2 558.4 583.1 Less current portion (22.6) (23.1) Long-term debt, net of current portion $ 535.8 $ 560.0 The following table shows scheduled principal payments due on long-term debt for the next five years (in millions): Amount October 1 through December 31, 2023 $ 5.8 2024 22.3 2025 21.2 2026 20.7 2027 490.4 Gross maturities 560.4 Less unamortized debt issuance costs (2.0) Total $ 558.4 In June 2022, the Company entered into a credit agreement (the “Credit Agreement”) that consists of a $400.0 million term loan A facility (the “Term Loan A Facility”) and a $350.0 million revolving credit facility (the “Revolving Credit Facility” and together with the Term Loan A Facility, the “Credit Facilities”). The Credit Facilities mature in June 2027. Interest on the loans under the Credit Facilities is calculated by reference to the Secured Overnight Financing Rate (“SOFR”) or an alternative base rate, plus an applicable interest rate margin. Enhabit may voluntarily prepay outstanding loans under the Credit Facilities at any time without premium or penalty, other than customary breakage costs with respect to SOFR loans. The Term Loan A Facility contains customary mandatory prepayments, including with respect to proceeds from asset sales and from certain incurrences of indebtedness. On June 30, 2022, we drew the full $400.0 million of the Term Loan A Facility and $170.0 million on the Revolving Credit Facility. The net proceeds of $566.6 million were distributed to Encompass prior to the completion of the Distribution. As of September 30, 2023, amounts drawn under the Term Loan A Facility and the Revolving Credit Facility had an interest rate of 7.7%. For additional information on the Separation, see Note 1, Summary of Significant Accounting Policies , to the accompanying unaudited condensed consolidated financial statements. The Term Loan A Facility amortizes by an amount per annum equal to 5.0% of the outstanding principal amount thereon as of the closing date, payable in equal quarterly installments, with the balance being payable in June 2027. The Revolving Credit Facility provides the ability to borrow and obtain letters of credit, which is subject to a $75.0 million sublimit. Obligations under the Credit Facilities are guaranteed by our existing and future wholly owned domestic material subsidiaries (the “Guarantors”), subject to certain exceptions. Borrowings under the Credit Facilities are secured by first priority liens on substantially all the assets of Enhabit and the Guarantors, subject to certain exceptions. The Credit Facilities contain representations and warranties, affirmative and negative covenants and events of default customary for secured financings of this type, including limitations with respect to liens, fundamental changes, indebtedness, restricted payments, investments and affiliate transactions, in each case, subject to a number of important exceptions and qualifications. On June 27, 2023, we amended the Credit Facilities to provide for, among other things, (i) a new tier to the pricing grid for interest rate margins when the total net leverage ratio exceeds 4.50 to 1.00; (ii) changes to the conditions concerning the Company’s total net leverage ratio that must be met for the Company to borrow incremental ratio-based amounts; (iii) an increase in the maximum permitted total net leverage ratio to 5.25 to 1.00 for the quarters ending June 30, 2023, September 30, 2023, and December 31, 2023, stepping down to 5.00 to 1.00 for the quarter ending March 31, 2024, 4.75 to 1.00 for the quarter ending June 30, 2024, and 4.50 to 1.00 for the quarter ending September 30, 2024 and thereafter; and (iv) modifications to the Company’s ability to declare and make certain restricted payments. On September 29, 2023, we entered into a Limited Waiver (the “Waiver”) with Wells Fargo Bank, National Association, as administrative agent to the other lenders (the “Administrative Agent”) under the Credit Agreement and the First Amendment to the Credit Agreement dated as of June 27, 2023. The Waiver released the Company from the requirement to comply with the total net leverage ratio and the interest coverage ratio covenants for the three months ended September 30, 2023. The Waiver also required that, until such time as the Company certifies compliance with the waived financial covenants, the aggregate principal amount of the Company’s revolving loans allowed under the Credit Agreement shall be decreased from $350.0 million to $230.0 million. All other covenants and terms of the Credit Agreement remain unchanged and in effect. Although we are not required to be in compliance with the financial covenants, as of September 30, 2023, we were in compliance with the financial covenants under the Credit Facilities. As of September 30, 2023, our forecasted results suggested there was uncertainty of meeting our covenants through a period of one year from the issuance date of the September 30, 2023 financial statements. As a result, on November 3, 2023, we amended the Credit Facilities to provide for, among other things, (i) an increase in the maximum permitted Total Net Leverage Ratio (as defined in the Credit Agreement) to 6.75 to 1.00 for the quarters ending December 31, 2023 and March 31, 2024, stepping down to 6.50 to 1.00 for the quarters ending June 30, September 30 and December 31, 2024, 5.75 to 1.00 for the quarter ending March 31, 2025, and 4.50 to 1.00 for the quarter ending June 30, 2025 and thereafter; (ii) the addition of a Fixed Charge Coverage Ratio (as defined in the Credit Agreement) covenant of 1.15 to 1.00 until the end of the Covenant Adjustment Period (as defined below); (iii) no Interest Coverage Ratio (as defined in the Credit Agreement) covenant until the end of the Covenant Adjustment Period; (iv) a permanent reduction in the revolving credit facility commitment from $350.0 million to $220.0 million; (v) an increase in the Applicable Commitment Fee (as defined in the Credit Agreement) during the Covenant Adjustment Period; (vi) suspension of the ability of the Company to request incremental commitments under the Credit Agreement during the Covenant Adjustment Period; (vii) an increase of 0.25% in the applicable interest rate margins on amounts outstanding under the Credit Agreement during the Covenant Adjustment Period; (viii) limits on the amount of cash the Company can keep on hand and outside the lender group during the Covenant Adjustment Period; and (ix) additional limits on permitted acquisitions, permitted indebtedness, permitted liens, restricted payments and permitted investments during the Covenant Adjustment Period. The “Covenant Adjustment Period” begins on the date of the Second Amendment and ends on the earlier of (a) the date that the Company provides evidence of compliance with the financial covenants in the Credit Agreement, as amended, for the fiscal quarter ended June 30, 2025 and (b) the date that the Company provides evidence of compliance with the financial covenants in the Credit Agreement as in effect immediately prior to the First Amendment for the applicable quarter. Under specified circumstances, including non-compliance with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, we may not be able to borrow under the Revolving Credit Facility. Additionally, violation of the covenants would result in an event of default under the Credit Facilities. A default that occurs, and is not cured within any applicable cure period or is not waived, would permit lenders to accelerate the maturity of the debt under the Credit Facilities and to foreclose upon any collateral securing the debt. As a result of the amendment above, our forecasted results indicate we will continue to be in compliance with those financial covenants through a period of one year from the issuance date of the September 30, 2023 financial statements. We cannot guarantee we will be in compliance with our financial covenants for each reporting period through a period of one year from the issuance date of the September 30, 2023 financial statements. We continually evaluate our expected compliance with the covenants described above and take all appropriate steps to proactively renegotiate such covenants when appropriate. On October 20, 2022, we entered into an interest rate swap to manage our exposure to interest rate movements for a portion of our Term Loan A Facility. The interest rate swap has a $200.0 million notional value and a maturity date of October 20, 2025. Beginning in October 2022, we receive the one-month SOFR and pay a fixed rate of interest of 4.3%. See Note 7, Derivative Instruments . The carrying amounts and estimated fair values of our long-term debt are presented in the following table (in millions): As of September 30, 2023 As of December 31, 2022 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Long-term debt: Advances under revolving credit facility $ 180.0 $ 180.0 $ 190.0 $ 190.0 Term loan A facility $ 373.1 $ 355.6 $ 387.9 $ 356.6 Finance lease obligations $ 5.3 $ 5.3 $ 5.2 $ 5.2 Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, Summary of Significant Accounting Policies—Fair Value Measurements , to the consolidated financial statements included in the Form 10-K.

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases	Leases: We lease office space, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2035. Our operating and finance leases generally have one In March 2023, we renewed the lease on our corporate headquarters office space for a term of 11 years. The lease commences on June 1, 2024 and expires in May 2035. In July 2023, we amended the lease on our corporate headquarters office space to consolidate our office space within the building. The minimum lease payment obligations due under the amended lease are $23.8 million. The components of lease costs are as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Operating lease cost: General and administrative expenses $ 5.0 $ 5.0 $ 15.0 $ 15.0 Finance lease cost: Amortization of right-of-use assets 0.8 0.9 2.3 2.9 Interest on lease liabilities 0.1 0.1 0.1 0.1 Total finance lease cost 0.9 1.0 2.4 3.0 Total lease cost $ 5.9 $ 6.0 $ 17.4 $ 18.0 Supplemental consolidated balance sheet information related to leases is as follows (in millions): Classification As of September 30, 2023 As of December 31, 2022 Assets Operating lease Operating lease right-of-use assets $ 60.0 $ 42.0 Finance lease (1) Property and equipment, net 9.8 10.1 Total lease assets $ 69.8 $ 52.1 Liabilities Current Liabilities: Operating lease Current portion of operating lease liabilities $ 12.7 $ 14.0 Finance lease Current portion of long-term debt 2.6 3.1 Noncurrent liabilities Operating lease Long-term operating lease liabilities, net of current portion 47.0 28.1 Finance lease Long-term debt, net of current portion 2.7 2.1 Total lease liabilities $ 65.0 $ 47.3 (1) Finance lease assets are recorded net of accumulated amortization of $20.3 million and $21.3 million as of September 30, 2023 and December 31, 2022, respectively. As of September 30, 2023 2022 Weighted Average Remaining Lease Term Operating lease 5.9 years 3.5 years Finance lease 2.5 years 1.8 years Weighted Average Discount Rate Operating lease 6.6 % 4.2 % Finance lease 4.4 % 2.6 % Maturities of lease liabilities as of September 30, 2023 are as follows (in millions): Operating Leases Finance Leases October 1 through December 31, 2023 $ 3.2 $ 0.8 2024 16.3 2.4 2025 13.4 1.3 2026 10.6 0.7 2027 7.8 0.4 2028 5.0 — 2029 and thereafter 17.5 — Total lease payments 73.8 5.6 Less: Interest portion (14.1) (0.3) Total lease liabilities $ 59.7 $ 5.3 Supplemental cash flow information related to our leases is as follows (in millions): Nine Months Ended 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12.0 $ 13.0 Financing cash flows from finance leases $ 2.6 $ 3.6 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 29.3 $ 5.9 Finance leases $ 2.7 $ 2.9
Leases	Leases: We lease office space, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2035. Our operating and finance leases generally have one In March 2023, we renewed the lease on our corporate headquarters office space for a term of 11 years. The lease commences on June 1, 2024 and expires in May 2035. In July 2023, we amended the lease on our corporate headquarters office space to consolidate our office space within the building. The minimum lease payment obligations due under the amended lease are $23.8 million. The components of lease costs are as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Operating lease cost: General and administrative expenses $ 5.0 $ 5.0 $ 15.0 $ 15.0 Finance lease cost: Amortization of right-of-use assets 0.8 0.9 2.3 2.9 Interest on lease liabilities 0.1 0.1 0.1 0.1 Total finance lease cost 0.9 1.0 2.4 3.0 Total lease cost $ 5.9 $ 6.0 $ 17.4 $ 18.0 Supplemental consolidated balance sheet information related to leases is as follows (in millions): Classification As of September 30, 2023 As of December 31, 2022 Assets Operating lease Operating lease right-of-use assets $ 60.0 $ 42.0 Finance lease (1) Property and equipment, net 9.8 10.1 Total lease assets $ 69.8 $ 52.1 Liabilities Current Liabilities: Operating lease Current portion of operating lease liabilities $ 12.7 $ 14.0 Finance lease Current portion of long-term debt 2.6 3.1 Noncurrent liabilities Operating lease Long-term operating lease liabilities, net of current portion 47.0 28.1 Finance lease Long-term debt, net of current portion 2.7 2.1 Total lease liabilities $ 65.0 $ 47.3 (1) Finance lease assets are recorded net of accumulated amortization of $20.3 million and $21.3 million as of September 30, 2023 and December 31, 2022, respectively. As of September 30, 2023 2022 Weighted Average Remaining Lease Term Operating lease 5.9 years 3.5 years Finance lease 2.5 years 1.8 years Weighted Average Discount Rate Operating lease 6.6 % 4.2 % Finance lease 4.4 % 2.6 % Maturities of lease liabilities as of September 30, 2023 are as follows (in millions): Operating Leases Finance Leases October 1 through December 31, 2023 $ 3.2 $ 0.8 2024 16.3 2.4 2025 13.4 1.3 2026 10.6 0.7 2027 7.8 0.4 2028 5.0 — 2029 and thereafter 17.5 — Total lease payments 73.8 5.6 Less: Interest portion (14.1) (0.3) Total lease liabilities $ 59.7 $ 5.3 Supplemental cash flow information related to our leases is as follows (in millions): Nine Months Ended 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12.0 $ 13.0 Financing cash flows from finance leases $ 2.6 $ 3.6 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 29.3 $ 5.9 Finance leases $ 2.7 $ 2.9

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes: Our effective income tax benefit rate for the three months ended September 30, 2023 was 26.7% compared to an effective income tax rate of 23.9% for the three months ended September 30, 2022. The higher benefit rate is primarily the result of comparatively favorable state income taxes during the third quarter of 2023. Our effective income tax benefit rate for the nine months ended September 30, 2023 was 11.9% compared to an effective income tax rate of 24.1% for the nine months ended September 30, 2022. The reduction of the tax rate was primarily the result of a goodwill impairment charge in the second quarter of 2023, a significant portion of which was a permanent book-tax difference. Prior to July 1, 2022, the Company joined Encompass in the filing of various consolidated federal, state, and local income tax returns and was a party to an income tax allocation agreement (the “Tax Sharing Agreement”). Under the Tax Sharing Agreement, the Company paid to or received from Encompass the amount, if any, by which Encompass’s income tax liability was affected by virtue of inclusion of the Company in the consolidated income tax returns of Encompass. Effectively, that arrangement resulted in the Company’s annual income tax provision being computed, with adjustments, as if the Company filed separate consolidated income tax returns. At the Distribution, the Company entered into the Tax Matters Agreement with Encompass, which terminated the existing Tax Sharing Agreement. The Tax Matters Agreement governs the Company’s respective rights, responsibilities, and obligations with respect to taxes (including responsibility for taxes arising in the ordinary course of business and taxes, if any, incurred as a result of any failure of the Distribution to qualify as tax-free for U.S. federal income tax purposes), entitlement to refunds, allocation of tax attributes, preparation of tax returns, control of tax contests, and other matters.

Derivative Instruments

Derivative Instruments	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	Derivative Instruments: In October 2022, we entered into an interest rate swap agreement with a notional value of $200.0 million with a maturity of October 20, 2025. See Note 4, Long-Term Debt . The activities of the cash flow hedge included in accumulated other comprehensive income for the three and nine months ended September 30, 2023 are presented in the following table (in millions): Three Months Ended September 30, Nine Months Ended 2023 2022 2023 2022 Balance at beginning of period $ 0.9 $ — $ (0.7) $ — Unrealized gain recognized in other comprehensive income, net of tax 1.1 — 3.0 — Reclassified to interest expense, net of tax (0.4) — (0.7) — Balance at end of period $ 1.6 $ — $ 1.6 $ — The fair value of derivative assets and liabilities within the consolidated balance sheets are presented in the following table (in millions): September 30, 2023 December 31, 2022 Prepaid and other current assets $ 1.9 $ 1.0 Other long-term assets (liabilities) 0.2 (2.0) Total $ 2.1 $ (1.0) Fair values for our interest rate swap agreement are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, Summary of Significant Accounting Policies—Fair Value Measurements , to the consolidated financial statements included in the Form 10-K.

Contingencies and Other Commitm

Contingencies and Other Commitments	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Commitments	Contingencies and Other Commitments:We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. The condensed consolidated balance sheets as of September 30, 2023 and December 31, 2022 include $1.2 million and $8.8 million, respectively, in Other current liabilities and Other current assets

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting: Our internal financial reporting and management structure is focused on the major types of services provided by the Company. We manage our operations using two operating segments that are also our reportable segments: (1) home health and (2) hospice. These reportable operating segments are consistent with information used by our Chief Executive Officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments: • Home Health - Our home health operations represent the nation’s fourth largest provider of Medicare-certified skilled home health services, measured by 2020 Medicare revenues. As of September 30, 2023, we operated 255 home health locations in 34 states, with a concentration in the southern half of the United States. We are the sole owner of 244 of these locations. We retain 50.0% to 81.0% ownership in the remaining 11 jointly owned locations. Our home health services include a comprehensive range of Medicare-certified home health nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. See Note 1, Summary of Significant Accounting Policies , to the consolidated financial statements included in the Form 10-K for a definition of episodic and non-episodic revenue. • Hospice - Our hospice business is one of the nation’s largest providers of Medicare-certified hospice services in terms of 2020 Medicare revenues. As of September 30, 2023, we operated 109 hospice locations in 23 states, with a concentration in the southern half of the United States. We are the sole owner of 105 of these locations. We retain 50.0% to 90.0% ownership in the remaining four jointly owned locations. Our hospice services include in-home services to terminally ill patients and their families to address patients’ physical needs, including pain control and symptom management, and to provide emotional and spiritual support. The accounting policies of our reportable segments are the same as those described in Note 1, Summary of Significant Accounting Policies , to the consolidated financial statements included in the Form 10-K. All revenues for our services are generated through external customers. See Note 1, Summary of Significant Accounting Policies—Net Service Revenue , for the disaggregation of our revenues. No corporate overhead is allocated to either of our reportable segments. Our Chief Executive Officer evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (“Segment Adjusted EBITDA”). Segment assets are not reviewed by our Chief Executive Officer and therefore are not disclosed below. Selected financial information for our reportable segments is as follows (in millions): Home Health Hospice Three Months Ended September 30, Three Months Ended September 30, 2023 2022 2023 2022 Net service revenue $ 210.9 $ 216.3 $ 47.4 $ 49.4 Cost of service, excluding depreciation and amortization 110.0 109.6 24.0 22.7 General and administrative expenses 59.0 61.9 15.7 17.3 Other income (0.1) — — — Noncontrolling interests 0.2 0.2 — 0.1 Segment Adjusted EBITDA $ 41.8 $ 44.6 $ 7.7 $ 9.3 Home Health Hospice Nine Months Ended Nine Months Ended 2023 2022 2023 2022 Net service revenue $ 640.5 $ 661.4 $ 145.2 $ 146.6 Cost of service, excluding depreciation and amortization 329.5 326.4 72.6 65.8 General and administrative expenses 181.3 178.4 48.0 47.7 Other income (0.2) — — — Noncontrolling interests 1.0 1.3 — 0.3 Segment Adjusted EBITDA $ 128.9 $ 155.3 $ 24.6 $ 32.8 Segment reconciliations (in millions): Three Months Ended September 30, Nine Months Ended 2023 2022 2023 2022 Total Segment Adjusted EBITDA $ 49.5 $ 53.9 $ 153.5 $ 188.1 Non-segment general and administrative expenses (31.0) (23.8) (90.6) (77.2) Depreciation and amortization (7.7) (8.0) (23.2) (24.7) Impairment of goodwill — — (85.8) — Interest expense and amortization of debt discounts and fees (10.9) (6.2) (30.7) (6.3) Net income attributable to noncontrolling interests 0.2 0.3 1.0 1.6 Stock-based compensation expense (3.1) (4.5) (7.2) (7.1) Other — — — (0.1) (Loss) income before income taxes and noncontrolling interests $ (3.0) $ 11.7 $ (83.0) $ 74.3 Additional detail regarding the revenues of our operating segments by service line follows (in millions): Three Months Ended September 30, Nine Months Ended 2023 2022 2023 2022 Home Health: Episodic $ 167.3 $ 181.8 $ 503.0 $ 559.8 Non-episodic 41.1 31.5 129.7 93.1 Other 2.5 3.0 7.8 8.5 Total home health 210.9 216.3 640.5 661.4 Hospice 47.4 49.4 145.2 146.6 Total net service revenue $ 258.3 $ 265.7 $ 785.7 $ 808.0

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions:In connection with the Separation, we entered into several agreements with Encompass that govern the relationship of the parties following the Distribution, including a Separation and Distribution Agreement, a Transition Services Agreement, a Tax Matters Agreement, and an Employee Matters Agreement. The Separation and Distribution Agreement contains provisions that, among other things, relate to (i) assets, liabilities, and contracts to be transferred, assumed, and assigned to each of Enhabit and Encompass as part of the Separation, (ii) cross-indemnities principally designed to place financial responsibility for the obligations and liabilities of the Enhabit business with Enhabit and financial responsibility for the obligations and liabilities of Encompass’s remaining business with Encompass, (iii) procedures with respect to claims subject to indemnification and related matters, (iv) the allocation between Enhabit and Encompass of rights and obligations under existing insurance policies with respect to occurrences prior to completion of the Distribution, as well as the right to proceeds and the obligation to incur certain deductibles under certain insurance policies, and (v) procedures governing Enhabit’s and Encompass’s obligations and allocations of liabilities with respect to ongoing litigation matters that may implicate each of Enhabit’s business and Encompass’s business. Allocation of Corporate Expenses Before the Separation, Encompass provided the Company with certain services, including, but not limited to, executive oversight, treasury, legal, accounting, human resources, tax, internal audit, financial reporting, information technology, and investor relations. Certain information technology services continue to be provided by Encompass to the Company on a temporary basis under the Transition Services Agreement. Our unaudited condensed consolidated financial statements through September 30, 2022 include an allocation of these costs for the periods prior to July 1, 2022. When specific identification is not practicable, a proportional cost method is used, primarily based on revenue and headcount. These cost allocations reasonably reflect these services and the benefits derived for the periods presented. These allocations may not be indicative of the actual expenses that would have been incurred as an independent, publicly traded company. In addition, the Company’s employees historically participated in Encompass’s various stock-based compensation plans. The allocations of services from Encompass to the Company of $7.7 million, including $2.5 million of stock-based compensation expense paid to employees of Encompass, were recorded in General and administrative expenses in the condensed consolidated statements of operations for the nine months ended September 30, 2022. For information related to our Tax Sharing Agreement with Encompass, see Note 6, Income Taxes . Data Analytics Investment During 2019, we made a $2.0 million investment in Medalogix, LLC, a healthcare predictive data and analytics company (“Medalogix”); this investment is accounted for under the measurement alternative for investments. During the three and nine months ended September 30, 2023 and 2022, we incurred costs of approximately $0.8 million and $1.1 million, and $3.2 million and $3.4 million, respectively, in connection with the usage of Medalogix’s analytics platforms. These costs are included in Cost of service , excluding depreciation and amortization and General and administrative expenses in the condensed consolidated statements of income.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (2.4)	$ 8.6	$ (74.1)	$ 54.8

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries should be read in conjunction with the audited consolidated financial statements and accompanying notes contained in the Company’s Annual Report for the year ended December 31, 2022 on Form 10-K (the “Form 10-K”) filed with the United States Securities and Exchange Commission (the “SEC”) on April 14, 2023. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December 31, 2022 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading.
Consolidation	The results related to the periods prior to July 1, 2022 included within the accompanying unaudited condensed consolidated financial statements have been derived from the unaudited condensed consolidated financial statements and accounting records of Encompass as if the Company had operated on a stand-alone basis during the periods presented and were prepared utilizing the legal entity approach, in accordance with GAAP, and pursuant to the rules and regulations of the SEC. Prior to July 1, 2022, the Company was reported as a single reportable segment within Encompass’s reportable segments and did not operate as a stand-alone company. Accordingly, Encompass historically reported the financial position and the related results of operations, cash flows, and changes in equity of the Company as a component of Encompass’s unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements include an allocation of expenses related to certain Encompass corporate functions as discussed in Note 10, Related Party Transactions, for periods prior to July 1, 2022. The unaudited condensed consolidated financial statements also include revenues and expenses directly attributable to the Company and assets and liabilities specifically attributable to the Company. Encompass’s third-party debt and related interest expense have not been attributed to the Company because the Company was not the primary legal obligor of the debt and the borrowings were not specifically identifiable to the Company. However, subsequent to April 23, 2020, the Company was a guarantor for Encompass’s credit agreement and senior debt. In connection with the Distribution, the Company was released from its guarantee of Encompass’s indebtedness. The Company maintains its own cash management system and did not participate in a centralized cash management arrangement with Encompass. The income tax amounts in these unaudited condensed consolidated financial statements for the periods prior to July 1, 2022 have been calculated based on a separate return methodology and are presented as if our income gave rise to separate federal and state consolidated income tax return filing obligations in the respective jurisdictions in which we operate. In addition to various separate state and local income tax filings, we joined with Encompass in various U.S. federal, state and local consolidated income tax filings prior to the Separation. See Note 6, Income Taxes , for information related to our Tax Sharing Agreement with Encompass. The unaudited condensed consolidated financial statements include the assets, liabilities, revenues, and expenses of all wholly owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest. We use the equity method to account for our investments in entities we do not control, but for which we have the ability to exercise significant influence over operating and financial policies. Consolidated Net (loss) income attributable to Enhabit, Inc. includes our share of the net earnings of these entities. We eliminate all intercompany accounts and transactions within the Company from our financial results. Transactions between the Company and Encompass have been included in these unaudited condensed consolidated financial statements. The transfers with Encompass that were not settled in cash are reflected in stockholders’ equity on the condensed consolidated balance sheets and within Capital in Excess of Par Value
Recent Accounting Pronouncements	Recent Accounting Pronouncements — We do not believe any recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of Disaggregation of Net Service Revenue by Payor Source and Segment	Our Net service revenue disaggregated by payor source and segment are as follows (in millions): Home Health Hospice Consolidated Three Months Ended Three Months Ended Three Months Ended 2023 2022 2023 2022 2023 2022 Medicare $ 141.0 $ 159.1 $ 46.7 $ 47.3 $ 187.7 $ 206.4 Medicare Advantage 45.7 38.5 — — 45.7 38.5 Managed care 21.2 15.2 — 1.7 21.2 16.9 Medicaid 2.9 3.3 0.7 0.4 3.6 3.7 Other 0.1 0.2 — — 0.1 0.2 Total $ 210.9 $ 216.3 $ 47.4 $ 49.4 $ 258.3 $ 265.7 Home Health Hospice Consolidated Nine Months Ended Nine Months Ended Nine Months Ended 2023 2022 2023 2022 2023 2022 Medicare $ 426.5 $ 492.5 $ 140.5 $ 141.4 $ 567.0 $ 633.9 Medicare Advantage 148.3 110.3 — — 148.3 110.3 Managed care 56.5 49.2 4.3 4.3 60.8 53.5 Medicaid 8.7 8.9 0.4 0.9 9.1 9.8 Other 0.5 0.5 — — 0.5 0.5 Total $ 640.5 $ 661.4 $ 145.2 $ 146.6 $ 785.7 $ 808.0
Schedule Of Net Income Attributable To Redeemable Noncontrolling Interest And Nonredeemable Noncontrolling Interests	The following tables reconcile the net income attributable to nonredeemable Noncontrolling interests , as recorded in the shareholders’ equity section of the consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests , as recorded in the mezzanine section of the consolidated balance sheets, to the Net income attributable to noncontrolling interests presented in the consolidated statements of income (in millions): Nine Months Ended September 30, 2023 2022 Balance at beginning of period $ 5.2 $ 5.0 Purchases of redeemable noncontrolling interests — 0.2 Distributions to redeemable noncontrolling interests (0.2) — Balance at end of period $ 5.0 $ 5.2 Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net income attributable to nonredeemable noncontrolling interests $ 0.3 $ 0.3 $ 1.0 $ 1.6 Net income attributable to redeemable noncontrolling interests (0.1) — — — Net income attributable to noncontrolling interests $ 0.2 $ 0.3 $ 1.0 $ 1.6
Schedule of Diluted Weighted Average Common Shares Outstanding	The following table sets forth the computation of diluted weighted average common shares outstanding for the three and nine months ended September 30, 2023 and 2022 (in millions): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Weighted average common shares outstanding: Basic 49.9 49.6 49.8 49.6 Dilutive effect of restricted stock, restricted stock units and performance units — 0.1 — 0.1 Diluted 49.9 49.7 49.8 49.7

Variable Interest Entities (V_2

Variable Interest Entities (VIEs) (Tables)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Variable Interest Entities	The carrying amounts and classifications of the consolidated VIEs’ assets and liabilities, which are included in our condensed consolidated balance sheets, are as follows (in millions): September 30, December 31, Assets Current assets: Restricted cash $ 3.0 $ 4.0 Accounts receivable 2.3 2.9 Total current assets 5.3 6.9 Operating lease right-of-use assets 0.1 0.2 Goodwill 12.4 12.4 Intangible assets, net 0.9 1.1 Total assets $ 18.7 $ 20.6 Liabilities Current liabilities: Current operating lease liabilities $ 0.1 $ 0.1 Accrued payroll 0.3 0.2 Other current liabilities 0.8 0.1 Total current liabilities 1.2 0.4 Long-term operating lease liabilities 0.1 — Other long-term liabilities — 0.1 Total liabilities $ 1.3 $ 0.5

Long-term Debt (Tables)

Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Outstanding	Our long-term debt outstanding consists of the following (in millions): September 30, December 31, 2022 Credit Agreement— Advances under revolving credit facility $ 180.0 $ 190.0 Term loan A facility 373.1 387.9 Finance lease obligations 5.3 5.2 558.4 583.1 Less current portion (22.6) (23.1) Long-term debt, net of current portion $ 535.8 $ 560.0
Schedule of Principal Payments Due on Long-term Debt	The following table shows scheduled principal payments due on long-term debt for the next five years (in millions): Amount October 1 through December 31, 2023 $ 5.8 2024 22.3 2025 21.2 2026 20.7 2027 490.4 Gross maturities 560.4 Less unamortized debt issuance costs (2.0) Total $ 558.4
Schedule of Carrying Values and Estimated Fair Values of Long-term Debt	The carrying amounts and estimated fair values of our long-term debt are presented in the following table (in millions): As of September 30, 2023 As of December 31, 2022 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Long-term debt: Advances under revolving credit facility $ 180.0 $ 180.0 $ 190.0 $ 190.0 Term loan A facility $ 373.1 $ 355.6 $ 387.9 $ 356.6 Finance lease obligations $ 5.3 $ 5.3 $ 5.2 $ 5.2

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Schedule of Components of Lease Costs	The components of lease costs are as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Operating lease cost: General and administrative expenses $ 5.0 $ 5.0 $ 15.0 $ 15.0 Finance lease cost: Amortization of right-of-use assets 0.8 0.9 2.3 2.9 Interest on lease liabilities 0.1 0.1 0.1 0.1 Total finance lease cost 0.9 1.0 2.4 3.0 Total lease cost $ 5.9 $ 6.0 $ 17.4 $ 18.0
Schedule of Supplemental Consolidated Balance Sheet Information	Supplemental consolidated balance sheet information related to leases is as follows (in millions): Classification As of September 30, 2023 As of December 31, 2022 Assets Operating lease Operating lease right-of-use assets $ 60.0 $ 42.0 Finance lease (1) Property and equipment, net 9.8 10.1 Total lease assets $ 69.8 $ 52.1 Liabilities Current Liabilities: Operating lease Current portion of operating lease liabilities $ 12.7 $ 14.0 Finance lease Current portion of long-term debt 2.6 3.1 Noncurrent liabilities Operating lease Long-term operating lease liabilities, net of current portion 47.0 28.1 Finance lease Long-term debt, net of current portion 2.7 2.1 Total lease liabilities $ 65.0 $ 47.3 (1) Finance lease assets are recorded net of accumulated amortization of $20.3 million and $21.3 million as of September 30, 2023 and December 31, 2022, respectively. As of September 30, 2023 2022 Weighted Average Remaining Lease Term Operating lease 5.9 years 3.5 years Finance lease 2.5 years 1.8 years Weighted Average Discount Rate Operating lease 6.6 % 4.2 % Finance lease 4.4 % 2.6 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of lease liabilities as of September 30, 2023 are as follows (in millions): Operating Leases Finance Leases October 1 through December 31, 2023 $ 3.2 $ 0.8 2024 16.3 2.4 2025 13.4 1.3 2026 10.6 0.7 2027 7.8 0.4 2028 5.0 — 2029 and thereafter 17.5 — Total lease payments 73.8 5.6 Less: Interest portion (14.1) (0.3) Total lease liabilities $ 59.7 $ 5.3 Supplemental cash flow information related to our leases is as follows (in millions): Nine Months Ended 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12.0 $ 13.0 Financing cash flows from finance leases $ 2.6 $ 3.6 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 29.3 $ 5.9 Finance leases $ 2.7 $ 2.9
Schedule of Maturities of Finance Lease Liabilities	Maturities of lease liabilities as of September 30, 2023 are as follows (in millions): Operating Leases Finance Leases October 1 through December 31, 2023 $ 3.2 $ 0.8 2024 16.3 2.4 2025 13.4 1.3 2026 10.6 0.7 2027 7.8 0.4 2028 5.0 — 2029 and thereafter 17.5 — Total lease payments 73.8 5.6 Less: Interest portion (14.1) (0.3) Total lease liabilities $ 59.7 $ 5.3 Supplemental cash flow information related to our leases is as follows (in millions): Nine Months Ended 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12.0 $ 13.0 Financing cash flows from finance leases $ 2.6 $ 3.6 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 29.3 $ 5.9 Finance leases $ 2.7 $ 2.9

Derivative Instruments (Tables)

Derivative Instruments (Tables)	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)	The activities of the cash flow hedge included in accumulated other comprehensive income for the three and nine months ended September 30, 2023 are presented in the following table (in millions): Three Months Ended September 30, Nine Months Ended 2023 2022 2023 2022 Balance at beginning of period $ 0.9 $ — $ (0.7) $ — Unrealized gain recognized in other comprehensive income, net of tax 1.1 — 3.0 — Reclassified to interest expense, net of tax (0.4) — (0.7) — Balance at end of period $ 1.6 $ — $ 1.6 $ —
Schedule of Derivative Assets at Fair Value	The fair value of derivative assets and liabilities within the consolidated balance sheets are presented in the following table (in millions): September 30, 2023 December 31, 2022 Prepaid and other current assets $ 1.9 $ 1.0 Other long-term assets (liabilities) 0.2 (2.0) Total $ 2.1 $ (1.0)
Schedule of Derivative Liabilities at Fair Value	The fair value of derivative assets and liabilities within the consolidated balance sheets are presented in the following table (in millions): September 30, 2023 December 31, 2022 Prepaid and other current assets $ 1.9 $ 1.0 Other long-term assets (liabilities) 0.2 (2.0) Total $ 2.1 $ (1.0)

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of Selected Financial Information	Selected financial information for our reportable segments is as follows (in millions): Home Health Hospice Three Months Ended September 30, Three Months Ended September 30, 2023 2022 2023 2022 Net service revenue $ 210.9 $ 216.3 $ 47.4 $ 49.4 Cost of service, excluding depreciation and amortization 110.0 109.6 24.0 22.7 General and administrative expenses 59.0 61.9 15.7 17.3 Other income (0.1) — — — Noncontrolling interests 0.2 0.2 — 0.1 Segment Adjusted EBITDA $ 41.8 $ 44.6 $ 7.7 $ 9.3 Home Health Hospice Nine Months Ended Nine Months Ended 2023 2022 2023 2022 Net service revenue $ 640.5 $ 661.4 $ 145.2 $ 146.6 Cost of service, excluding depreciation and amortization 329.5 326.4 72.6 65.8 General and administrative expenses 181.3 178.4 48.0 47.7 Other income (0.2) — — — Noncontrolling interests 1.0 1.3 — 0.3 Segment Adjusted EBITDA $ 128.9 $ 155.3 $ 24.6 $ 32.8
Schedule of Segment Reconciliation	Segment reconciliations (in millions): Three Months Ended September 30, Nine Months Ended 2023 2022 2023 2022 Total Segment Adjusted EBITDA $ 49.5 $ 53.9 $ 153.5 $ 188.1 Non-segment general and administrative expenses (31.0) (23.8) (90.6) (77.2) Depreciation and amortization (7.7) (8.0) (23.2) (24.7) Impairment of goodwill — — (85.8) — Interest expense and amortization of debt discounts and fees (10.9) (6.2) (30.7) (6.3) Net income attributable to noncontrolling interests 0.2 0.3 1.0 1.6 Stock-based compensation expense (3.1) (4.5) (7.2) (7.1) Other — — — (0.1) (Loss) income before income taxes and noncontrolling interests $ (3.0) $ 11.7 $ (83.0) $ 74.3
Schedule of Additional Detail Regarding Revenues by Service Line	Additional detail regarding the revenues of our operating segments by service line follows (in millions): Three Months Ended September 30, Nine Months Ended 2023 2022 2023 2022 Home Health: Episodic $ 167.3 $ 181.8 $ 503.0 $ 559.8 Non-episodic 41.1 31.5 129.7 93.1 Other 2.5 3.0 7.8 8.5 Total home health 210.9 216.3 640.5 661.4 Hospice 47.4 49.4 145.2 146.6 Total net service revenue $ 258.3 $ 265.7 $ 785.7 $ 808.0

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) $ / shares in Units, shares in Millions, $ in Millions		3 Months Ended		9 Months Ended
	Jul. 01, 2022 $ / shares	Sep. 30, 2023 USD ($) state $ / shares shares	Sep. 30, 2022 shares	Sep. 30, 2023 USD ($) segment state $ / shares shares	Sep. 30, 2022 shares	Dec. 31, 2022 $ / shares
Class of Stock [Line Items]
Number of states in which entity operates | state		34		34
Number of reportable segments | segment				2
Common stock, par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01		$ 0.01		$ 0.01
Stock conversion ratio	0.5
Deferred tax liabilities | $		$ 31		$ 31
Options
Class of Stock [Line Items]
Antidilutive securities (in shares) | shares		0.3	0.2	0.3	0.2
Restricted Stock, Performance Units, And Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Antidilutive securities (in shares) | shares		1.5	0.7	1.5	0.7
Trade Name
Class of Stock [Line Items]
Finite lived intangible asset | $		$ 135.2		$ 135.2

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Disaggregation of Net Service Revenue by Payor Source and Segment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Net service revenue	$ 258.3	$ 265.7	$ 785.7	$ 808
Medicare
Disaggregation of Revenue [Line Items]
Net service revenue	187.7	206.4	567	633.9
Medicare Advantage
Disaggregation of Revenue [Line Items]
Net service revenue	45.7	38.5	148.3	110.3
Managed care
Disaggregation of Revenue [Line Items]
Net service revenue	21.2	16.9	60.8	53.5
Medicaid
Disaggregation of Revenue [Line Items]
Net service revenue	3.6	3.7	9.1	9.8
Other
Disaggregation of Revenue [Line Items]
Net service revenue	0.1	0.2	0.5	0.5
Home Health
Disaggregation of Revenue [Line Items]
Net service revenue	210.9	216.3	640.5	661.4
Home Health | Medicare
Disaggregation of Revenue [Line Items]
Net service revenue	141	159.1	426.5	492.5
Home Health | Medicare Advantage
Disaggregation of Revenue [Line Items]
Net service revenue	45.7	38.5	148.3	110.3
Home Health | Managed care
Disaggregation of Revenue [Line Items]
Net service revenue	21.2	15.2	56.5	49.2
Home Health | Medicaid
Disaggregation of Revenue [Line Items]
Net service revenue	2.9	3.3	8.7	8.9
Home Health | Other
Disaggregation of Revenue [Line Items]
Net service revenue	0.1	0.2	0.5	0.5
Hospice
Disaggregation of Revenue [Line Items]
Net service revenue	47.4	49.4	145.2	146.6
Hospice | Medicare
Disaggregation of Revenue [Line Items]
Net service revenue	46.7	47.3	140.5	141.4
Hospice | Medicare Advantage
Disaggregation of Revenue [Line Items]
Net service revenue	0	0	0	0
Hospice | Managed care
Disaggregation of Revenue [Line Items]
Net service revenue	0	1.7	4.3	4.3
Hospice | Medicaid
Disaggregation of Revenue [Line Items]
Net service revenue	0.7	0.4	0.4	0.9
Hospice | Other
Disaggregation of Revenue [Line Items]
Net service revenue	$ 0	$ 0	$ 0	$ 0

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule Of Net Income Attributable To Redeemable Noncontrolling Interest And Nonredeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning of period			$ 5.2	$ 5
Purchases of redeemable noncontrolling interests			0	0.2
Distributions to redeemable noncontrolling interests			(0.2)	0
Balance at end of period	$ 5	$ 5.2	5	5.2
Net income attributable to nonredeemable noncontrolling interests	0.3	0.3	1	1.6
Net income attributable to redeemable noncontrolling interests	(0.1)	0	0	0
Net income attributable to noncontrolling interests	$ 0.2	$ 0.3	$ 1	$ 1.6

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Diluted Weighted Average Common Shares Outstanding (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Weighted average common shares outstanding:
Basic (in shares)	49.9	49.6	49.8	49.6
Dilutive effect of restricted stock, restricted stock units and performance units (in shares)	0	0.1	0	0.1
Diluted (in shares)	49.9	49.7	49.8	49.7

Variable Interest Entities (V_3

Variable Interest Entities (VIEs) - Additional Information (Details) - VIE, Primary Beneficiary - entity	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Variable Interest Entity [Line Items]
Number of entities consolidated	2	2
Minimum
Variable Interest Entity [Line Items]
Ownership percentage	60%
Maximum
Variable Interest Entity [Line Items]
Ownership percentage	90%

Variable Interest Entities (V_4

Variable Interest Entities (VIEs) (Details) - USD ($) $ in Millions		Sep. 30, 2023	Dec. 31, 2022
Current assets:
Restricted cash		$ 3.6	$ 4.3
Accounts receivable		167.8	149.6
Total current assets		217.8	211.8
Operating lease right-of-use assets		60	42
Goodwill		1,061.7	1,144.8
Intangible assets, net		85.9	102.6
Total assets	[1]	1,450.9	1,526.8
Liabilities
Current operating lease liabilities		12.7	14
Accrued payroll		48.6	35.5
Other current liabilities		36.9	40.7
Total current liabilities		143	132.9
Long-term operating lease liabilities		47	28.1
Other long-term liabilities		0	1.9
Total liabilities		742.1	751.5
VIE, Primary Beneficiary
Current assets:
Restricted cash		3	4
Accounts receivable		2.3	2.9
Total current assets		5.3	6.9
Operating lease right-of-use assets		0.1	0.2
Goodwill		12.4	12.4
Intangible assets, net		0.9	1.1
Total assets		18.7	20.6
Liabilities
Current operating lease liabilities		0.1	0.1
Accrued payroll		0.3	0.2
Other current liabilities		0.8	0.1
Total current liabilities		1.2	0.4
Long-term operating lease liabilities		0.1	0
Other long-term liabilities		0	0.1
Total liabilities		$ 1.3	$ 0.5
[1] Our consolidated assets as of September 30, 2023 and December 31, 2022 include total assets of variable interest entities of $18.7 million and $20.6 million, respectively, that cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September 30, 2023 and December 31, 2022 include total liabilities of the variable interest entities of $1.3 million and $0.5 million, respectively. See Note 2, Variable Interest Entities .

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Details)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($) unit	Jun. 30, 2023 USD ($) unit	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) unit
Goodwill [Line Items]
Number of reporting units | unit	2	2					2
Impairment of goodwill	$ 0			$ 0	$ 85,800,000	$ 0
Goodwill	1,061,700,000		$ 1,144,800,000		1,061,700,000		$ 1,144,800,000
Accumulated impairment loss	$ 194,800,000		109,000,000		$ 194,800,000		$ 109,000,000
Home Health Reporting Unit
Goodwill [Line Items]
Impairment of goodwill			$ 109,000,000
Reporting unit, percentage of fair value in excess of carrying amount	7%				7%
Goodwill	$ 843,900,000	$ 843,900,000			$ 843,900,000
Hospice Reporting Unit
Goodwill [Line Items]
Impairment of goodwill		85,800,000
Reporting unit, percentage of fair value in excess of carrying amount	5%		15%		5%		15%
Goodwill	$ 217,800,000	$ 217,800,000	$ 303,600,000		$ 217,800,000		$ 303,600,000

Long-term Debt - Schedule of Lo

Long-term Debt - Schedule of Long-Term Debt Outstanding (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Finance lease obligations	$ 5.3	$ 5.2
Long term debt including current maturities	558.4	583.1
Less current portion	(22.6)	(23.1)
Long-term debt, net of current portion	535.8	560
Line of Credit | Enhabit Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt	180	190
Line of Credit | Enhabit Credit Agreement | Term loan A facility
Debt Instrument [Line Items]
Long-term debt	$ 373.1	$ 387.9

Long-term Debt - Schedule of Pr

Long-term Debt - Schedule of Principal Payments Due on Long-term Debt (Details) $ in Millions	Sep. 30, 2023 USD ($)
Amount
October 1 through December 31, 2023	$ 5.8
2024	22.3
2025	21.2
2026	20.7
2027	490.4
Gross maturities	560.4
Less unamortized debt issuance costs	(2)
Total	$ 558.4

Long-term Debt - Additional Inf

Long-term Debt - Additional Information (Details)					1 Months Ended	9 Months Ended
	Nov. 03, 2023 USD ($)	Nov. 02, 2023 USD ($)	Jun. 27, 2023	Jun. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 29, 2023 USD ($)	Oct. 31, 2022 USD ($)	Oct. 20, 2022 USD ($)
Debt Instrument [Line Items]
Principal borrowings on term loan						$ 0	$ 400,000,000
Borrowings on revolving credit facility						0	170,000,000
Distributions to Encompass						$ 0	$ 654,900,000
Interest Rate Swap
Debt Instrument [Line Items]
Notional amount									$ 200,000,000	$ 200,000,000
Fixed interest rate (as percent)										4.30%
Enhabit Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Distributions to Encompass				$ 566,600,000
Interest rate (as percent)						7.70%
Term loan A facility | Enhabit Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Debt instrument, face amount				400,000,000	$ 400,000,000
Principal borrowings on term loan				400,000,000
Percentage of outstanding principal payable in equal quarterly installments					5%
Coverage leverage ratio, maximum			4.50
Term loan A facility | Enhabit Credit Agreement | Credit Agreement | Covenant Period, One
Debt Instrument [Line Items]
Debt instrument, maximum permitted total net leverage ratio			5.25
Term loan A facility | Enhabit Credit Agreement | Credit Agreement | Covenant Period, Two
Debt Instrument [Line Items]
Debt instrument, maximum permitted total net leverage ratio			5
Term loan A facility | Enhabit Credit Agreement | Credit Agreement | Covenant Period, Three
Debt Instrument [Line Items]
Debt instrument, maximum permitted total net leverage ratio			4.75
Term loan A facility | Enhabit Credit Agreement | Credit Agreement | Thereafter
Debt Instrument [Line Items]
Debt instrument, maximum permitted total net leverage ratio			4.50
Term loan A facility | The Second Amendment | Credit Agreement | Subsequent Event
Debt Instrument [Line Items]
Coverage leverage ratio, maximum	6.75
Debt instrument, maximum permitted total net leverage ratio	1.15
Term loan A facility | The Second Amendment | Credit Agreement | Covenant Period, One | Subsequent Event
Debt Instrument [Line Items]
Debt instrument, maximum permitted total net leverage ratio	6.50
Term loan A facility | The Second Amendment | Credit Agreement | Covenant Period, Two | Subsequent Event
Debt Instrument [Line Items]
Debt instrument, maximum permitted total net leverage ratio	5.75
Term loan A facility | The Second Amendment | Credit Agreement | Thereafter | Subsequent Event
Debt Instrument [Line Items]
Debt instrument, maximum permitted total net leverage ratio	4.50
Revolving Credit Facility | Enhabit Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				350,000,000	$ 350,000,000
Borrowings on revolving credit facility				170,000,000
Revolving Credit Facility | The Waiver | Minimum | Administrative Agent
Debt Instrument [Line Items]
Debt instrument, face amount								$ 230,000,000
Revolving Credit Facility | The Waiver | Maximum | Administrative Agent
Debt Instrument [Line Items]
Debt instrument, face amount								$ 350,000,000
Revolving Credit Facility | The Second Amendment | Credit Agreement | Subsequent Event
Debt Instrument [Line Items]
Commitment fee amount	$ 220,000,000	$ 350,000,000
Interest rate margins	0.25%
Letter of Credit | Enhabit Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				$ 75,000,000	$ 75,000,000

Long-term Debt - Schedule of Ca

Long-term Debt - Schedule of Carrying Values and Estimated Fair Values of Long-term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Line of Credit | Enhabit Credit Agreement | Carrying Amount | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, fair value	$ 180	$ 190
Line of Credit | Enhabit Credit Agreement | Carrying Amount | Term loan A facility
Debt Instrument [Line Items]
Long-term debt, fair value	373.1	387.9
Line of Credit | Enhabit Credit Agreement | Estimated Fair Value | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, fair value	180	190
Line of Credit | Enhabit Credit Agreement | Estimated Fair Value | Term loan A facility
Debt Instrument [Line Items]
Long-term debt, fair value	355.6	356.6
Finance lease obligations | Carrying Amount
Debt Instrument [Line Items]
Long-term debt, fair value	5.3	5.2
Finance lease obligations | Estimated Fair Value
Debt Instrument [Line Items]
Long-term debt, fair value	$ 5.3	$ 5.2

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Lessee, Lease, Description [Line Items]
Minimum lease payment obligations	$ 73.8
Corporate Headquarters
Lessee, Lease, Description [Line Items]
Lessee, operating lease, renewal term (in years)		11 years
Minimum lease payment obligations	$ 23.8
Minimum
Lessee, Lease, Description [Line Items]
Finance lease, term of contract (in years)	1 year
Operating lease, term of contract (in years)	1 year
Maximum
Lessee, Lease, Description [Line Items]
Finance lease, term of contract (in years)	8 years
Operating lease, term of contract (in years)	8 years

Leases - Schedule of Components

Leases - Schedule of Components of Lease Costs (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
General and administrative expenses	$ 5	$ 5	$ 15	$ 15
Finance lease cost:
Amortization of right-of-use assets	0.8	0.9	2.3	2.9
Interest on lease liabilities	0.1	0.1	0.1	0.1
Total finance lease cost	0.9	1	2.4	3
Total lease cost	$ 5.9	$ 6	$ 17.4	$ 18

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Consolidated Balance Sheet Information (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
Assets
Operating lease	$ 60	$ 42
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment, net	Property and equipment, net
Finance lease	$ 9.8	$ 10.1
Total lease assets	69.8	52.1
Liabilities
Operating lease, current liabilities	$ 12.7	$ 14
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Current portion of long-term debt	Current portion of long-term debt
Finance lease, current liabilities	$ 2.6	$ 3.1
Operating lease, noncurrent liabilities	$ 47	$ 28.1
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term debt, net of current portion	Long-term debt, net of current portion
Finance lease, noncurrent liabilities	$ 2.7	$ 2.1
Total lease liabilities	65	47.3
Finance lease, accumulated amortization	$ 20.3	$ 21.3
Weighted Average Remaining Lease Term
Operating lease	5 years 10 months 24 days		3 years 6 months
Finance lease	2 years 6 months		1 year 9 months 18 days
Weighted Average Discount Rate
Operating lease	6.60%		4.20%
Finance lease	4.40%		2.60%

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Lease Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Operating Leases
October 1 through December 31, 2023	$ 3.2
2024	16.3
2025	13.4
2026	10.6
2027	7.8
2028	5
2029 and thereafter	17.5
Total lease payments	73.8
Less: Interest portion	(14.1)
Total lease liabilities	59.7
Finance Leases
October 1 through December 31, 2023	0.8
2024	2.4
2025	1.3
2026	0.7
2027	0.4
2028	0
2029 and thereafter	0
Total lease payments	5.6
Less: Interest portion	(0.3)
Finance lease obligations	$ 5.3	$ 5.2

Leases - Schedule of Suppleme_2

Leases - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 12	$ 13
Financing cash flows from finance leases	2.6	3.6
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	29.3	5.9
Property and equipment additions through finance leases	$ 2.7	$ 2.9

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Effective income tax rate reconciliation, percent	26.70%	23.90%	11.90%	24.10%

Derivative Instruments - Additi

Derivative Instruments - Additional Information (Details) - USD ($)	Oct. 31, 2022	Oct. 20, 2022
Interest Rate Swap
Derivative [Line Items]
Notional amount	$ 200,000,000	$ 200,000,000

Derivative Instruments - Schedu

Derivative Instruments - Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance at beginning of period	$ 702.1	$ 850.7	$ 770.1	$ 1,478.3
Unrealized gain recognized in other comprehensive income, net of tax	0.7	0	2.3	0
Balance at end of period	703.8	863.8	703.8	863.8
Interest Rate Swap | Cash Flow Hedging
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance at beginning of period	0.9	0	(0.7)	0
Unrealized gain recognized in other comprehensive income, net of tax	1.1	0	3	0
Reclassified to interest expense, net of tax	(0.4)	0	(0.7)	0
Balance at end of period	$ 1.6	$ 0	$ 1.6	$ 0

Derivative Instruments - Sche_2

Derivative Instruments - Schedule of Derivative Assets and Liabilities at Fair Value (Details) - Interest Rate Swap - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Derivative [Line Items]
Total	$ 2.1	$ (1)
Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Prepaid and other current assets	1.9	1
Other Long-term Liabilities
Derivative [Line Items]
Prepaid and other current assets	$ 0.2
Other long-term assets (liabilities)		$ (2)

Contingencies and Other Commi_2

Contingencies and Other Commitments (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Loss contingency, estimate of possible loss	$ 1.2	$ 8.8

Segment Reporting - Additional

Segment Reporting - Additional Information (Details)	9 Months Ended
	Sep. 30, 2023 location state segment
Segment Reporting Information [Line Items]
Number of reportable segments | segment	2
Number of states in which entity operates | state	34
Home Health
Segment Reporting Information [Line Items]
Number of agencies	255
Number of states in which entity operates | state	34
Number of agencies with sole ownership	244
Number of jointly owned home health locations	11
Home Health | Minimum
Segment Reporting Information [Line Items]
Joint venture, ownership percentage	50%
Home Health | Maximum
Segment Reporting Information [Line Items]
Joint venture, ownership percentage	81%
Hospice
Segment Reporting Information [Line Items]
Number of agencies	109
Number of states in which entity operates | state	23
Number of agencies with sole ownership	105
Number of jointly owned home health locations	4
Hospice | Minimum
Segment Reporting Information [Line Items]
Joint venture, ownership percentage	50%
Hospice | Maximum
Segment Reporting Information [Line Items]
Joint venture, ownership percentage	90%

Segment Reporting - Schedule of

Segment Reporting - Schedule of Selected Financial Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Net service revenue	$ 258.3	$ 265.7	$ 785.7	$ 808
Cost of service, excluding depreciation and amortization	134	132.3	402.1	392.3
General and administrative expenses	108.8	107.5	327.1	310.4
Other income	(0.1)	0	(0.2)	0
Noncontrolling interests	0.2	0.3	1	1.6
Home Health
Segment Reporting Information [Line Items]
Net service revenue	210.9	216.3	640.5	661.4
Cost of service, excluding depreciation and amortization	110	109.6	329.5	326.4
General and administrative expenses	59	61.9	181.3	178.4
Other income	(0.1)	0	(0.2)	0
Noncontrolling interests	0.2	0.2	1	1.3
Segment Adjusted EBITDA	41.8	44.6	128.9	155.3
Hospice
Segment Reporting Information [Line Items]
Net service revenue	47.4	49.4	145.2	146.6
Cost of service, excluding depreciation and amortization	24	22.7	72.6	65.8
General and administrative expenses	15.7	17.3	48	47.7
Other income	0	0	0	0
Noncontrolling interests	0	0.1	0	0.3
Segment Adjusted EBITDA	$ 7.7	$ 9.3	$ 24.6	$ 32.8

Segment Reporting - Schedule _2

Segment Reporting - Schedule of Segment Reconciliation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Non-segment general and administrative expenses	$ (108,800,000)	$ (107,500,000)	$ (327,100,000)	$ (310,400,000)
Depreciation and amortization	(7,700,000)	(8,000,000)	(23,200,000)	(24,700,000)
Impairment of goodwill	0	0	(85,800,000)	0
Interest expense and amortization of debt discounts and fees	(10,900,000)	(6,200,000)	(30,700,000)	(6,300,000)
Net income attributable to noncontrolling interests	200,000	300,000	1,000,000	1,600,000
Other income	100,000	0	200,000	0
(Loss) income before income taxes and noncontrolling interests	(3,000,000)	11,700,000	(83,000,000)	74,300,000
Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total Segment Adjusted EBITDA	49,500,000	53,900,000	153,500,000	188,100,000
Segment Reconciling Items
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Non-segment general and administrative expenses	(31,000,000)	(23,800,000)	(90,600,000)	(77,200,000)
Depreciation and amortization	(7,700,000)	(8,000,000)	(23,200,000)	(24,700,000)
Impairment of goodwill	0	0	(85,800,000)	0
Interest expense and amortization of debt discounts and fees	(10,900,000)	(6,200,000)	(30,700,000)	(6,300,000)
Net income attributable to noncontrolling interests	200,000	300,000	1,000,000	1,600,000
Stock-based compensation expense	(3,100,000)	(4,500,000)	(7,200,000)	(7,100,000)
Other income	$ 0	$ 0	$ 0	$ (100,000)

Segment Reporting - Schedule _3

Segment Reporting - Schedule of Additional Detail Regarding Revenues by Service Line (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue from External Customer [Line Items]
Total net service revenue	$ 258.3	$ 265.7	$ 785.7	$ 808
Home Health
Revenue from External Customer [Line Items]
Total net service revenue	210.9	216.3	640.5	661.4
Hospice
Revenue from External Customer [Line Items]
Total net service revenue	47.4	49.4	145.2	146.6
Episodic | Home Health
Revenue from External Customer [Line Items]
Total net service revenue	167.3	181.8	503	559.8
Non-episodic | Home Health
Revenue from External Customer [Line Items]
Total net service revenue	41.1	31.5	129.7	93.1
Other | Home Health
Revenue from External Customer [Line Items]
Total net service revenue	$ 2.5	$ 3	$ 7.8	$ 8.5

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2019
Related Party Transaction [Line Items]
General and administrative expenses	$ 108.8	$ 107.5	$ 327.1	$ 310.4
Medalogix, LLC
Related Party Transaction [Line Items]
Payments to acquire investment					$ 2
Overhead Expense | Related Party
Related Party Transaction [Line Items]
General and administrative expenses				7.7
Share-Based Compensation Expense | Related Party
Related Party Transaction [Line Items]
General and administrative expenses				2.5
Medalogix Analytics Platforms | Related Party
Related Party Transaction [Line Items]
Cost of service, excluding depreciation and amortization and General and administrative expenses	$ 0.8	$ 3.2	$ 1.1	$ 3.4